10-Q: IR-Med Inc. Reports Q2 2024 Results, Faces Going Concern Uncertainty Amidst Product Launch Preparations

IR-Med, Inc. reported its Q2 2024 financial results, highlighting a decrease in operating expenses and net loss, while also noting substantial doubt about its ability to continue as a going concern.

Summary

• IR-Med, Inc. released its unaudited condensed consolidated financial statements for the quarter ended June 30, 2024.
• The company reported a net loss of $1.023 million for the six months ended June 30, 2024, compared to a loss of $2.459 million for the same period in 2023.
• Research and development expenses decreased significantly from $1.101 million to $289,000 for the six-month periods, primarily due to the completion of the PressureSafe device development.
• Marketing expenses also decreased from $334,000 to $196,000, and general and administrative expenses decreased from $1.017 million to $531,000 for the six-month periods.
• The company's cash and cash equivalents stood at $753,000 as of June 30, 2024, with total liabilities of $524,000.
• IR-Med is preparing for the commercial launch of its PressureSafe device, which received FDA listing certification in April 2024, with a planned launch in September 2024.
• The company is also developing a second product, DiaSafe, for the early detection of diabetic foot ulcers, supported by a grant from the Israel Innovation Authority (IIA).
• The company has raised $755,000 through private placements of common stock and warrants in June and July 2024.
• Management has expressed substantial doubt about the company's ability to continue as a going concern due to ongoing losses and insufficient cash resources.

Sentiment

Score: 3

Explanation: The document highlights significant financial challenges, including substantial losses, a going concern warning, and a breach of contract. While there are some positive developments, such as the FDA listing and reduced operating expenses, the overall sentiment is negative due to the company's precarious financial situation.

Positives

• The company's net loss decreased significantly year-over-year, indicating improved cost management.
• Research and development expenses decreased due to the completion of the PressureSafe device development.
• The company secured a grant from the IIA for the development of the DiaSafe device.
• The PressureSafe device received FDA listing certification, paving the way for commercial launch.
• The company successfully raised additional capital through private placements.

Negatives

• The company has incurred significant losses and has an accumulated deficit of $15.862 million.
• The company's cash resources are not sufficient to cover operating expenses for the next 12 months.
• Management has expressed substantial doubt about the company's ability to continue as a going concern.
• The company has not generated any revenue from product sales to date.
• The company is involved in a legal proceeding with a claim of approximately $2.1 million.

Risks

• The company's ability to continue as a going concern is uncertain due to insufficient cash resources.
• The company may need to raise additional capital, which may not be available on acceptable terms or at all.
• The company's research and development activities and marketing efforts may be delayed due to the ongoing Iron Swords War in Israel.
• The company is dependent on third-party manufacturers for device production.
• The company is involved in a legal proceeding with a claim of approximately $2.1 million.
• The company's distribution agreement is in breach of contract.

Future Outlook

The company plans to launch the commercial version of the PressureSafe device in September 2024 and continue the development of the DiaSafe device. The company also plans to seek additional financing arrangements to support its operations and development programs.

Management Comments

• Management has expressed substantial doubt about the company's ability to continue as a going concern.
• Management plans to continue development and marketing of its products, as well as seeking additional financing arrangements.
• Management believes that the general conditions have brought further difficulties in managements efforts to seek additional financing arrangements.
• Management assesses that the current events and the escalation in security in Israel, may have a material effect on its business plans in the short term and may cause delays in the Companys research and development activities and in its marketing efforts.

Industry Context

The company operates in the medical device industry, focusing on non-invasive diagnostic devices. The development of PressureSafe and DiaSafe addresses the need for early detection of pressure injuries and diabetic foot ulcers, which are significant healthcare challenges. The company's technology platform, combining infrared spectroscopy and AI, is aimed at providing more accurate and timely diagnostic information.

Comparison to Industry Standards

• IR-Med's focus on non-invasive diagnostic devices aligns with a growing trend in the medical device industry towards less invasive and more patient-friendly solutions.
• The company's technology platform, combining infrared spectroscopy and AI, is similar to approaches used by companies like Masimo (for non-invasive patient monitoring) and Senseonics (for continuous glucose monitoring), although IR-Med is targeting different medical indications.
• The company's financial results, particularly the significant losses and going concern uncertainty, are not uncommon for early-stage medical device companies that are still in the development and pre-commercialization phase. Companies like InMode and Shockwave Medical, which have successfully commercialized their products, have also experienced similar challenges in their early stages.
• The company's reliance on third-party manufacturers is a common practice in the medical device industry, with companies like Medtronic and Stryker also using contract manufacturers for some of their products.
• The company's need for additional capital is typical for medical device companies in the development phase, as they often require significant funding to complete clinical trials, obtain regulatory approvals, and establish commercial operations.

Management Changes

Legal Proceedings

• A lawsuit was filed against the company, the subsidiary, and Mr. Aharon Klein, seeking damages of approximately $2.1 million.
• The company believes that the allegations are baseless and without merit and intends to vigorously defend its rights.

Related Party Transactions

• Certain stockholders granted loans to the company to finance operations.
• One shareholder provided a loan to the company to finance operations.
• Certain shareholders entered into a convertible bridge loan agreement with the company.
• The company entered into amendments to the consulting agreements with Mr. Aharon Klein and Dr. Yaniv Cohen.

Stakeholder Impact

• Shareholders face significant risk due to the company's financial instability and going concern uncertainty.
• Employees may be affected by potential cost-cutting measures or delays in development programs.
• Customers may experience delays in the commercial launch of the PressureSafe device.
• Suppliers may face uncertainty due to the company's financial challenges.
• Creditors face increased risk due to the company's financial instability.

Next Steps

• The company plans to launch the commercial version of the PressureSafe device in September 2024.
• The company plans to continue the development of the DiaSafe device.
• The company plans to seek additional financing arrangements to support its operations and development programs.

Key Dates

Keywords

medical devices, infrared spectroscopy, artificial intelligence, pressure injuries, diabetic foot ulcers, FDA listing, going concern, financial results, research and development, private placement